Drugs / QUINUPRISTIN/DALFOPRISTIN
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | SYNERCID | — | 1999-09-21 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00240747 | Jun 2000 → Jan 2005 | gram-positive bacterial infections | Pfizer | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QUINUPRISTIN/DALFOPRISTIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137691 ↗ |
| Known as | Synercid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00240747 ↗ |
| Route | Intravenous | “I.V. Synercid” NCT00240747 ↗ |